• Publications
  • Influence
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
Treatment of hepatitis C virus (HCV) infection has progressed considerably with the approval of interferon-free, direct-acting antiviral (DAA)-based combination therapies. Although most treatedExpand
  • 374
  • 30
Structural biology of hepatitis C virus
Hepatitis C virus (HCV) causes acute and chronic liver disease in humans, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Studies of this virus have been hampered by the lack ofExpand
  • 434
  • 22
New hepatitis C therapies: the toolbox, strategies, and challenges.
Therapy for hepatitis C is undergoing a revolution. Several new drugs against the hepatitis C virus (HCV) have reached the market and many others, including direct-acting antivirals and host-targetedExpand
  • 443
  • 17
  • PDF
Treatment failure and resistance with direct‐acting antiviral drugs against hepatitis C virus
Current treatment of chronic hepatitis C virus (HCV) infection is based on the combination of pegylated interferon‐α and ribavirin. The recent development of direct‐acting antiviral (DAA) moleculesExpand
  • 325
  • 17
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
BACKGROUND & AIMS We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection andExpand
  • 250
  • 12
  • PDF
From non-A, non-B hepatitis to hepatitis C virus cure.
The hepatitis C virus (HCV) was discovered in the late 1980s. Interferon (IFN)-α was proposed as an antiviral treatment for chronic hepatitis C at about the same time. Successive improvements inExpand
  • 234
  • 12
Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.
This study examined the relationships between hepatitis C virus (HCV) genotypes and the routes of HCV transmission in 101 patients with chronic hepatitis C. Patients who received blood transfusionsExpand
  • 359
  • 11
The hepatitis C virus life cycle as a target for new antiviral therapies.
The burden of disease consequent to hepatitis C virus (HCV) infection has been well described and is expected to increase dramatically over the next decade. Current approved antiviral therapies areExpand
  • 324
  • 11
Interferon Resistance of Hepatitis C Virus Genotype 1b: Relationship to Nonstructural 5A Gene Quasispecies Mutations
ABSTRACT A 40-amino-acid sequence located in the nonstructural 5A (NS5A) protein of hepatitis C virus genotype 1b (HCV-1b) was recently suggested to be the interferon sensitivity-determining regionExpand
  • 209
  • 11
  • PDF
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.
Treatment of chronic hepatitis B virus (HBV) infection is aimed at suppressing viral replication to the lowest possible level, and thereby to halt the progression of liver disease and prevent theExpand
  • 238
  • 10